[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet",
    "summary": "Read the latest analysis on Vertex stock and its recent earnings report here.",
    "url": "https://finnhub.io/api/news?id=457a1ccd7b4be1b5d342bea5428a17588b135225edd16dc75e6355592dcbb4c3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755009259,
      "headline": "Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet",
      "id": 136321094,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148319783/image_2148319783.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Read the latest analysis on Vertex stock and its recent earnings report here.",
      "url": "https://finnhub.io/api/news?id=457a1ccd7b4be1b5d342bea5428a17588b135225edd16dc75e6355592dcbb4c3"
    }
  },
  {
    "ts": null,
    "headline": "GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s full-year revenue guidance of $28.5 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $2.01 per share was 2.7% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=94f1bc61789c28c544fe07fb1ec763eb70129c401ce2bac6d6c9143b8f9fabeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754983758,
      "headline": "GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus",
      "id": 136316170,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1.8% year on year to $7.08 billion. On the other hand, the company’s full-year revenue guidance of $28.5 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $2.01 per share was 2.7% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=94f1bc61789c28c544fe07fb1ec763eb70129c401ce2bac6d6c9143b8f9fabeb"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc. (NASDAQ:GILD) has received a favorable opinion from the European Medicines Agency’s CHMP for lenacapavir (Yeytuo®), a twice-yearly injectable HIV PrEP alternative. It will be the first of its kind in the EU if it is […]",
    "url": "https://finnhub.io/api/news?id=7963176ef804352359b79c89a19e4083edf1af02eba21a44185bd8f2c3634456",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754957985,
      "headline": "Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir",
      "id": 136316171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc. (NASDAQ:GILD) has received a favorable opinion from the European Medicines Agency’s CHMP for lenacapavir (Yeytuo®), a twice-yearly injectable HIV PrEP alternative. It will be the first of its kind in the EU if it is […]",
      "url": "https://finnhub.io/api/news?id=7963176ef804352359b79c89a19e4083edf1af02eba21a44185bd8f2c3634456"
    }
  }
]